Search research articles
Contact Us
Filters
Showing results (11-20 of 256) with videos related to
Page
of 26
Sort By:
Dermatologic Clinics
|
November 22, 2014
Pharmacogenomics and the resulting impact on psoriasis therapies
Amy C Foulkes, Richard B Warren
Drugs in Context
|
April 27, 2019
Brodalumab in psoriasis: evidence to date and clinical potential
Amy C Foulkes, Richard B Warren
Dermatology and Therapy
|
March 18, 2019
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature
David Rutkowski, Hector Chinoy, Richard B Warren
Seminars in Cutaneous Medicine and Surgery
|
May 1, 2010
The future of biological therapies
Richard B Warren, Christopher E M Griffiths
Expert Review of Clinical Immunology
|
December 31, 2013
Treating moderate to severe psoriasis - best use of biologics
Maeve Lynch, Brian Kirby, Richard B Warren
American Journal of Clinical Dermatology
|
March 1, 2016
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
Zenas Z N Yiu, Richard B Warren
Clinics in Dermatology
|
August 30, 2008
Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine
Richard B Warren, Christopher E M Griffiths
Expert Opinion on Investigational Drugs
|
January 3, 2017
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
Zenas Z N Yiu, Richard B Warren
Immunotherapy
|
February 26, 2015
Efficacy and safety of emerging immunotherapies in psoriasis
Zenas Z N Yiu, Richard B Warren
Clinical Pharmacology and Therapeutics
|
July 13, 2017
Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist
Zenas Z N Yiu, Richard B Warren
Page
of 26
Search research articles
Search
Showing results (11-20 of 256) with videos related to
Sort By:
Page
of 26
Dermatologic Clinics
|
November 22, 2014
Pharmacogenomics and the resulting impact on psoriasis therapies
Amy C Foulkes, Richard B Warren
Drugs in Context
|
April 27, 2019
Brodalumab in psoriasis: evidence to date and clinical potential
Amy C Foulkes, Richard B Warren
Dermatology and Therapy
|
March 18, 2019
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature
David Rutkowski, Hector Chinoy, Richard B Warren
Seminars in Cutaneous Medicine and Surgery
|
May 1, 2010
The future of biological therapies
Richard B Warren, Christopher E M Griffiths
Expert Review of Clinical Immunology
|
December 31, 2013
Treating moderate to severe psoriasis - best use of biologics
Maeve Lynch, Brian Kirby, Richard B Warren
American Journal of Clinical Dermatology
|
March 1, 2016
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
Zenas Z N Yiu, Richard B Warren
Clinics in Dermatology
|
August 30, 2008
Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine
Richard B Warren, Christopher E M Griffiths
Expert Opinion on Investigational Drugs
|
January 3, 2017
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
Zenas Z N Yiu, Richard B Warren
Immunotherapy
|
February 26, 2015
Efficacy and safety of emerging immunotherapies in psoriasis
Zenas Z N Yiu, Richard B Warren
Clinical Pharmacology and Therapeutics
|
July 13, 2017
Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist
Zenas Z N Yiu, Richard B Warren
Page
of 26